• CorMedix Inc CRMD.OQ reported quarterly adjusted earnings of 28 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -25 cents. The mean expectation of seven analysts for the quarter was for earnings of 17 cents per share. Wall Street expected results to range from 6 cents to 25 cents per share.

• Revenue rose 4,829.4% to $39.74 million from a year ago; analysts expected $34.03 million.

• CorMedix Inc's reported EPS for the quarter was 28 cents​.

• The company reported quarterly net income of $19.83 million.

• CorMedix Inc shares had fallen by 18.5% this quarter and gained 25.0% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 40.2% in the last three months.​

• In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy"

• Wall Street's median 12-month price target for CorMedix Inc is $19.50, about 48.4% above its last closing price of $10.06

This summary was machine generated from LSEG data August 12 at 01:30 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)